8 results
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
DPP-4 Inhibitors ... - Pharmacology ... failure Common Side Effects ... #Inhibitors #Pharmacology ... #Summary #DM2 #diabetes
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors ... titrate up to effects ... only few side effects ... #Dosing #Pharmacology ... #Management #Diabetes
Clinically Significant Cardiovascular Drug-Drug Interactions With OTC Supplements and Herbal Products
Angiotensin-Converting Enzyme Inhibitors (ACEIs)
 • Night-blooming
Cardiovascular Drug-Drug ... Angiotensin-Converting Enzyme Inhibitors ... Monoamine Oxidase Inhibitors ... supplementals #herbal #pharmacology ... #DDI #table #cardiology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
Common side effects ... There is an ORAL ... very similar to DPP4s ... GLP1 #Agonists #Pharmacology ... #Dosing #Diabetes
Veltassa (Patiromer) 
MECHANISM: Potassium Binder 
INDICATION: Treatment of Hyperkalemia 
FORMULATION: Powder for oral suspension 
DOSING: 8.4
suspension DOSING ... with CKD, HF, or diabetes ... ACE inhibitors, ... Most common side effect ... #Hyperkalemia #Pharmacology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
-1 Agonist Dosing ... to remain stable ... empagliflozin and DPP4 ... #semaglutide #Diabetes ... #Pharmacology #
Allopurinol Pharmacology Summary

Xanthine oxidase inhibitor blocking the formation of new uric acid
Initiate 1-2 days prior to
Xanthine oxidase inhibitor ... chemotherapy Dosing ... 10mL/min Side effects ... hypersensitivity Drug ... pathophysiology #gout
Pheochromocytoma - Diagnosis and Management Summary
10 percent rule = 10% of pheochromocytomas are extra-adrenal, multiple, bilateral,
Symptoms and Signs ... or with certain drugs ... monoamine oxidase inhibitors ... apparent type 2 diabetes ... the vasodilatory effect